Arachidonate Products and CYP1A in Dioxin Toxicity
Arachidonate Products and CYP1A in Dioxin Toxicity
批准号:
7880924
负责人:
ARLEEN B. RIFKIND
金额:
$52.12万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-09-30 至 2012-06-30
关键词:
AffectAgeAnimal ModelArachidonic AcidsAryl Hydrocarbon ReceptorBindingCYP1A2 geneCaloric RestrictionCarbohydratesCardiacCardiotoxicityCardiovascular DiseasesCardiovascular systemCellsCessation of lifeChick EmbryoCultured CellsCyclic AMP-Dependent Protein KinasesCytochrome P450DataDepressed moodDevelopmentDiabetes MellitusDioxinsDiseaseEatingEnergy MetabolismEnergy-Generating ResourcesEnvironmentEnzyme InductionEnzymesEpoxy CompoundsFailureFatty AcidsFigs - dietaryFoodFunctional disorderFundingGallus gallus CYP1A5 proteinGene TargetingGenesGenetic TranscriptionGluconeogenesisGlucoseGrantHeartHepaticHepatocyteHumanImmune System and Related DisordersIon ChannelIschemiaLeadLearningLigandsLipidsLiteratureLiverMalignant NeoplasmsMammalian CellMammalsMediatingMembrane LipidsMetabolicMetabolismMethodsMitochondriaModelingMolecularMusMuscle functionMyocardiumNADPNutrientOrganOrthologous GenePathologicPathway interactionsPhosphoenolpyruvate CarboxylasePhysiologicalPhysiologyPrimordiumProcessProductionProgress ReportsPublic HealthRattusReactive Oxygen SpeciesReceptor ActivationRegulatory PathwayRelianceReperfusion TherapyResearchResearch DesignRetroviral VectorRoleRouteSchemeSignal PathwaySignal TransductionSourceStagingStudy modelsTechniquesTestingTetrachlorodibenzodioxinToxic Environmental SubstancesToxic effectTumor PromotionVertebratesWasting Syndromeactivating transcription factorarachidonatebasefatty acid oxidationfollow-upglucose-6-phosphatasehatchinghepatic gluconeogenesishuman diseaseimprovedin vivolipid metabolismnovelnovel strategiesnutrient metabolismoverexpressionoxidationreceptorresponsetool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Binding and activation of the Ah receptor (AhR) is required for the environmental toxin 2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD, dioxin) to produce its toxic effects. TCDD toxicity includes a lethal wasting syndrome and cardiovascular dysfunction, but it is not known how TCDD activation of the AhR produces those effects. This research seeks to understand how TCDD activation of the AhR leads to suppression of gluconeogenesis, energy failure and death and to identify contributions of cytochrome P450 (CYP) 1A enzymes, the major transcriptional products of AhR activation, to the toxicity. The following hypothesis will be tested: (1) Transcriptional and posttranslational effects of TCDD on signaling pathways converging on PGC1?, i.e. Akt, AMPK, PKA and Sirt1, contribute to suppression of gluconeogensis by TCDD. PGC1? governs transcription of PEPCK and glucose 6-phosphatase, regulators of flux through the gluconeogenic pathway; (2) Suppression of gluconeogenesis forces reliance on lipids for energy but also limits availability of lipids as a fuel source; (3) Effects of TCDD on CYP-dependent metabolism of the membrane lipid arachidonic acid (aa) contribute to energy failure in liver and heart. The research will follow up on discoveries under prior funding periods of the grant that TCDD causes cardiac contractile dysfunction and increases hepatic formation of CYP-dependent aa epoxides, EETs, and decreases formation of 20-HETE, aa products with major physiologic cardiovascular regulatory effects, to examine their involvement in nutrient metabolism. TCDD will be used as a tool to learn how AhR activation and changes in CYP-dependent aa metabolism can lead to physiologic disturbances in glucose and lipid metabolism involved in the wasting syndrome (specific aim (SA) 1) and in ion channel and cardiac muscle function (SA2). Studies in SA2 will also determine whether increased production of EETs in liver affect the heart and are cardioprotective or cardiotoxic. The chick embryo close to hatching will continue to be used as the major model based on its track record in studying TCDD toxicity, its similarity to humans with respect to aa metabolism and its special utility for this research in permitting hepatic metabolic effects to be studied independently of confounding effects of food intake. Findings will be confirmed in mammalian cells. Definitive evidence for or against a role of CYP1A in AhR effects will be sought by silencing or overexpressing CYP1A4 and CYP1A5 in chick embryo hepatocytes and by a novel molecular approach in which sense and antisense CYP1A gene constructs in retroviral vectors will be targeted to liver or heart in chick embryos at early stages of development and the effects examined at a later stages. This research is expected to show that CYP1A enzymes contribute to metabolic and cardiovascular regulatory pathways, to improve understanding about relationships between glucose and lipid metabolism and the role of the AhR in regulating physiologic and pathologic responses to changes in nutrient availability, and to have implications for common related diseases, cardiovascular disease and diabetes. Relevance: Responses to changes in nutrient supply and metabolism contribute to aging and common human diseases including diabetes, cardiovascular disease and cancer. The environmental toxin, TCDD, by the single action of binding to the aryl hydrocarbon receptor (AhR), which is present in all our cells, initiates a lethal wasting syndrome characterized by a failure to synthesize glucose and leading to energy failure and death. By learning how TCDD activation of the AhR produces massive dysregulation of nutrient responses we expect to learn more about how the body normally orchestrates responses to changing levels of nutrients and how normal regulatory processes can spin out of control, with implications for common human diseases as well as normal physiology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of AHR Metabolic Toxicity
-
批准号:9219030
-
项目类别:
-
资助金额:$45.08万
-
财政年份:2017
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
Mechanisms of AHR Metabolic Toxicity
-
批准号:9888381
-
项目类别:
-
资助金额:$44.96万
-
财政年份:2017
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
Arachidonate Products and CYP1A in Dioxin Toxicity
-
批准号:7636784
-
项目类别:
-
资助金额:$51.12万
-
财政年份:2007
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
Arachidonate Products and CYP1A in Dioxin Toxicity
-
批准号:7386288
-
项目类别:
-
资助金额:$49.18万
-
财政年份:2007
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
Arachidonate Products and CYP1A in Dioxin Toxicity
-
批准号:7501910
-
项目类别:
-
资助金额:$49.63万
-
财政年份:2007
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
Arachidonate Products and CYP1A in Dioxin Toxicity
-
批准号:8092537
-
项目类别:
-
资助金额:$51.53万
-
财政年份:2007
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
ARACHIDONATE PRODUCTS IN DIOXIN AND PCB TOXICITY
-
批准号:3251067
-
项目类别:
-
资助金额:$20.01万
-
财政年份:1984
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
ARACHIDONATE PRODUCTS IN DIOXIN AND PCB TOXICITY
-
批准号:6839965
-
项目类别:
-
资助金额:$46.76万
-
财政年份:1984
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
ARACHIDONATE PRODUCTS IN DIOXIN AND PCB TOXICITY
-
批准号:3251064
-
项目类别:
-
资助金额:$2.05万
-
财政年份:1984
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
ARACHIDONATE PRODUCTS IN DIOXIN AND PCB TOXICITY
-
批准号:3251072
-
项目类别:
-
资助金额:$28.98万
-
财政年份:1984
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
ARACHIDONATE PRODUCTS IN DIOXIN AND PCB TOXICITY
-
批准号:3251062
-
项目类别:
-
资助金额:$20.23万
-
财政年份:1984
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
ARACHIDONATE PRODUCTS IN DIOXIN AND PCB TOXICITY
-
批准号:3251066
-
项目类别:
-
资助金额:$6.81万
-
财政年份:1984
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
ARACHIDONATE PRODUCTS IN DIOXIN AND PCB TOXICITY
-
批准号:2518621
-
项目类别:
-
资助金额:$44.89万
-
财政年份:1984
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
ARACHIDONATE PRODUCTS IN DIOXIN AND PCB TOXICITY
-
批准号:2770712
-
项目类别:
-
资助金额:$46.11万
-
财政年份:1984
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
ARACHIDONATE PRODUCTS IN DIOXIN AND PCB TOXICITY
-
批准号:3251070
-
项目类别:
-
资助金额:$25.47万
-
财政年份:1984
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
ARACHIDONATE PRODUCTS IN DIOXIN AND PCB TOXICITY
-
批准号:3251060
-
项目类别:
-
资助金额:$15.57万
-
财政年份:1984
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
ARACHIDONATE PRODUCTS IN DIOXIN AND PCB TOXICITY
-
批准号:6627001
-
项目类别:
-
资助金额:$44.08万
-
财政年份:1984
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
ARACHIDONATE PRODUCTS IN DIOXIN AND PCB TOXICITY
-
批准号:6693852
-
项目类别:
-
资助金额:$45.4万
-
财政年份:1984
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
ARACHIDONATE PRODUCTS IN DIOXIN AND PCB TOXICITY
-
批准号:2153361
-
项目类别:
-
资助金额:$42.44万
-
财政年份:1984
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
ARACHIDONATE PRODUCTS IN DIOXIN AND PCB TOXICITY
-
批准号:2153362
-
项目类别:
-
资助金额:$43.73万
-
财政年份:1984
-
负责人:ARLEEN B. RIFKIND
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: